News / FDA
FDA Rejects Replimune Skin Cancer Therapy RP1: What This Means for Patients
The FDA has rejected Replimune Group's RP1, a viral-based therapy intended for advanced skin cancer, due to inadequate trial data. This decision highlights the agency's increasingly stringent approach to new drug approvals and raises concer...